1
|
Garai J, Krekó M, Őrfi L, Jakus PB, Rumbus Z, Kéringer P, Garami A, Vámos E, Kovács D, Bagóné Vántus V, Radnai B, Lóránd T. Tetralone derivatives are MIF tautomerase inhibitors and attenuate macrophage activation and amplify the hypothermic response in endotoxemic mice. J Enzyme Inhib Med Chem 2021; 36:1357-1369. [PMID: 34225560 PMCID: PMC8266241 DOI: 10.1080/14756366.2021.1916010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/30/2022] Open
Abstract
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine playing crucial role in immunity. MIF exerts a unique tautomerase enzymatic activity that has relevance concerning its multiple functions and its small molecule inhibitors have been proven to block its pro-inflammatory effects. Here we demonstrate that some of the E-2-arylmethylene-1-tetralones and their heteroanalogues efficiently bind to MIF's active site and inhibit MIF tautomeric (enolase, ketolase activity) functions. A small set of the synthesised derivatives, namely compounds (4), (23), (24), (26) and (32), reduced inflammatory macrophage activation. Two of the selected compounds (24) and (26), however, markedly inhibited ROS and nitrite production, NF-κB activation, TNF-α, IL-6 and CCL-2 cytokine expression. Pre-treatment of mice with compound (24) exaggerated the hypothermic response to high dose of bacterial endotoxin. Our experiments suggest that tetralones and their derivatives inhibit MIF's tautomeric functions and regulate macrophage activation and thermal changes in severe forms of systemic inflammation.
Collapse
Affiliation(s)
- János Garai
- Department of Pathophysiology, Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary
| | - Marcell Krekó
- Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary
| | - László Őrfi
- Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary
| | - Péter Balázs Jakus
- Department of Biochemistry and Medical Chemistry, University of Pécs, Medical School, Pécs, Hungary
| | - Zoltán Rumbus
- Department of Thermophysiology, Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary
| | - Patrik Kéringer
- Department of Thermophysiology, Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary
| | - András Garami
- Department of Thermophysiology, Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary
| | - Eszter Vámos
- Department of Biochemistry and Medical Chemistry, University of Pécs, Medical School, Pécs, Hungary
| | - Dominika Kovács
- Department of Biochemistry and Medical Chemistry, University of Pécs, Medical School, Pécs, Hungary
| | - Viola Bagóné Vántus
- Department of Biochemistry and Medical Chemistry, University of Pécs, Medical School, Pécs, Hungary
| | - Balázs Radnai
- Department of Biochemistry and Medical Chemistry, University of Pécs, Medical School, Pécs, Hungary
| | - Tamás Lóránd
- Department of Biochemistry and Medical Chemistry, University of Pécs, Medical School, Pécs, Hungary
| |
Collapse
|
2
|
Abstract
Macrophage migration inhibitory factor (MIF) is an upstream regulator of the immune response whose dysregulation is tied to a broad spectrum of inflammatory and proliferative disorders. As its complex signaling pathways and pleiotropic nature have been elucidated, it has become an attractive target for drug discovery. Remarkably, MIF is both a cytokine and an enzyme that functions as a keto-enol tautomerase. Strategies including in silico modeling, virtual screening, high-throughput screening, and screening of anti-inflammatory natural products have led to a large and diverse catalogue of MIF inhibitors as well as some understanding of the structure-activity relationships for compounds binding MIF's tautomerase active site. With possible clinical trials of some MIF inhibitors on the horizon, it is an opportune time to review the literature to seek trends, address inconsistencies, and identify promising new avenues of research.
Collapse
Affiliation(s)
- Vinay Trivedi-Parmar
- Department of Chemistry , Yale University , New Haven , Connecticut 06520-8107 , United States
| | - William L Jorgensen
- Department of Chemistry , Yale University , New Haven , Connecticut 06520-8107 , United States
| |
Collapse
|
3
|
Al-Sha'er MA, VanPatten S, Al-Abed Y, Taha MO. Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors. J Mol Graph Model 2013; 42:104-14. [PMID: 23603608 DOI: 10.1016/j.jmgm.2013.03.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2013] [Revised: 03/14/2013] [Accepted: 03/16/2013] [Indexed: 11/19/2022]
Abstract
Recent research suggested the involvement of migration inhibitor factor (MIF) in cancer and inflammatory diseases, which prompted several attempts to develop new MIF inhibitors. Accordingly, we investigated the pharmacophoric space of 79 MIF inhibitors using seven diverse subsets of inhibitors to identify plausible binding hypotheses (pharmacophores). Subsequently, we implemented genetic algorithm and multiple linear regression analysis to select optimal combination of pharmacophores and physicochemical descriptors capable of explaining bioactivity variation within the training compounds (QSAR model, r63=0.62, F=42.8, rLOO(2)=0.721,rPRESS(2) against 16 external test inhibitors=0.58). Two orthogonal pharmacophores appeared in the optimal QSAR model suggestive of at least two binding modes available to ligands inside MIF binding pocket. Subsequent validation using receiver operating characteristic (ROC) curves analysis established the validity of these two pharmacophores. We employed these pharmacophoric models and associated QSAR equation to screen the National Cancer Institute (NCI) list of compounds. Eight compounds gave >50% inhibition at 100μM. Two molecules illustrated >75% inhibition at 10μM.
Collapse
|
4
|
Vera PL, Iczkowski KA, Howard DJ, Jiang L, Meyer-Siegler KL. Antagonism of macrophage migration inhibitory factor decreases cyclophosphamide cystitis in mice. Neurourol Urodyn 2010; 29:1451-7. [DOI: 10.1002/nau.20878] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
5
|
McLean LR, Zhang Y, Li H, Li Z, Lukasczyk U, Choi YM, Han Z, Prisco J, Fordham J, Tsay JT, Reiling S, Vaz RJ, Li Y. Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening. Bioorg Med Chem Lett 2009; 19:6717-20. [PMID: 19836948 DOI: 10.1016/j.bmcl.2009.09.106] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2009] [Revised: 09/25/2009] [Accepted: 09/29/2009] [Indexed: 10/20/2022]
Abstract
Biochemical and X-ray crystallographic studies confirmed that hydroxyquinoline derivatives identified by virtual screening were actually covalent inhibitors of the MIF tautomerase. Adducts were formed by N-alkylation of the Pro-1 at the catalytic site with a loss of an amino group of the inhibitor.
Collapse
Affiliation(s)
- Larry R McLean
- Discovery Research, sanofi-aventis, Bridgewater, NJ 08807, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|